Japan
Kyushu University - Kyushu University Hospital
Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy
Epidermal growth factor receptor (EGFR)Tyrosine kinase inhibitorOsimertinibTumor sizePrimary lesion